Prosensa Holding

Prosensa Holding B.V. devel­ops ther­a­peu­tics on the basis of RNA mod­u­la­tion, thereby inter­ven­ing in an inter­me­di­ate step in pro­tein biosyn­the­sis.

The company’s lead pro­gram is in Duchenne Muscular Dystrophy (DMD), a genetic dis­or­der that blocks the syn­the­sis of an impor­tant pro­tein. DMD leads to pro­gres­sive paral­y­sis and even­tu­ally to death. No treat­ment exists today.

Portfolio: MedSciences Capital B.V. and MedSciences Capital II B.V.

Current prod­uct devel­op­ment stage: phase III clin­i­cal tri­als.